It is a highly cardioselective vasodilatory beta1 receptor blocker used in treatment of hypertension. We have positioned ourselves as a dependable firm, engaged in offering Nebivolol HCL. It is a competitive and highly selective beta-1 receptor antagonist with mild vasodilating properties, possibly due to an interaction with the L-arginine/nitric oxide pathway. In preclinical studies, Nebivolol HCL has been shown to induce endothelium-dependent arterial relaxation in a dose dependent manner, by stimulation of the release of endothelial nitric oxide. Nitric oxide acts to relax vascular smooth muscle cells and inhibits platelet aggregation and adhesion.